Valeant Pharmaceuticals International, Inc. (VRX) Tops Q4 EPS by 10c

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q4 EPS of $0.94, $0.10 better than the analyst estimate of $0.84. Revenue for the quarter came in at $688.4 million, versus $514.56 million reported last year.

For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c